Involvement of CD5+CD19+Cell in steroid-dependent nephrotic syndrome treated with B-cell targeting therapy

Pediatr Int. 2013 Feb;55(1):99-101. doi: 10.1111/j.1442-200X.2012.03616.x.

Abstract

We showed in this study the longitudinal changes of the B-cell counts in patients with steroid-dependent nephrotic syndrome (SDNS) treated with cyclophosphamide (CPM) and mycophenolate mofetil (MMF). In our case with SDNS, this combined therapy not only decreased B-cell counts but also increased CD5(+) CD19(+) (CD5(+) B)/ CD5(-) CD19(+) (CD5-B) cell ratio. Recurrence was not observed when an elevated CD5(+) B/CD5⁻B [corrected] cell ratio was maintained even after the B cells increased. Therefore, this ratio might be more important than the whole B-cell counts. The changes of this ratio could be a good predictor of the clinical course of the patients treated with B-cell targeting therapy.

Publication types

  • Case Reports

MeSH terms

  • Antigens, CD19 / metabolism*
  • B-Lymphocyte Subsets / metabolism*
  • Biomarkers / metabolism
  • CD5 Antigens / metabolism*
  • Child, Preschool
  • Cyclophosphamide / therapeutic use*
  • Drug Therapy, Combination
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Lymphocyte Count
  • Male
  • Mycophenolic Acid / analogs & derivatives*
  • Mycophenolic Acid / therapeutic use
  • Nephrotic Syndrome / drug therapy*
  • Nephrotic Syndrome / immunology

Substances

  • Antigens, CD19
  • Biomarkers
  • CD5 Antigens
  • Immunosuppressive Agents
  • Cyclophosphamide
  • Mycophenolic Acid